Harmonizing Safety and Speed: A Human-Algorithm Approach to Enhance the FDA's Medical Device Clearance Policy

TL;DR

This paper presents a data-driven, human-algorithm hybrid approach to improve the FDA's 510(k) medical device clearance process by reducing recall rates and workload, leading to significant safety and cost benefits.

Contribution

It introduces machine learning models to predict recall risks and a new clearance policy that enhances safety and efficiency over current FDA practices.

Findings

32.9% reduction in recall rate

40.5% decrease in regulatory workload

Approximately $1.7 billion annual cost savings

Abstract

The United States Food and Drug Administration's (FDA's) 510(k) pathway allows manufacturers to gain medical device approval by demonstrating substantial equivalence to a legally marketed device. However, the inherent ambiguity of this regulatory procedure has been associated with high recall among many devices cleared through this pathway, raising significant safety concerns. In this paper, we develop a combined human-algorithm approach to assist the FDA in improving its 510(k) medical device clearance process by reducing recall risk and regulatory workload. We first develop machine learning methods to estimate the risk of recall of 510(k) medical devices based on the information available at the time of submission. We then propose a data-driven clearance policy that recommends acceptance, rejection, or deferral to FDA's committees for in-depth evaluation. We conduct an empirical study using a unique dataset of over 31,000 submissions that we assembled based on data sources from the FDA and Centers for Medicare and Medicaid Service (CMS). Compared to the FDA's current practice, which has a recall rate of 10.3% and a normalized workload measure of 100%, a conservative evaluation of our policy shows a 32.9% improvement in the recall rate and a 40.5% reduction in the workload. Our analyses further suggest annual cost savings of approximately $1.7 billion for the healthcare system driven by avoided replacement costs, which is equivalent to 1.1% of the entire United States annual medical device expenditure. Our findings highlight the value of a holistic and data-driven approach to improve the FDA's current 510(k) pathway.